ACOR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 Apr 2024 @ 16:00):

Stats
Today's Volume	321 668
Average Volume	136 656
Market Cap	821 028
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0120 (1.96%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-22	Burns Thomas M.	Buy	2 400	Non-Employee Stock Option
2023-06-22	Burns Thomas M.	Buy	0
2023-06-22	Varian John	Buy	1 200	Non-Employee Stock Option
2023-06-22	Panem Sandra Phd	Buy	1 200	Non-Employee Stock Option
2023-06-22	Kelley John P	Buy	1 200	Non-Employee Stock Option

INSIDER POWER
99.30
Last 96 transactions
Buy: 1 532 806 \| Sell: 94 790

Volume Correlation

Long: -0.43 (neutral)

Short: -0.79 (moderate negative)

Signal:(18.947) Neutral

Acorda Therapeutics Inc Correlation

10 Most Positive Correlations
HCTI	0.95
TVTX	0.945
ALBO	0.939
MNST	0.934
CMPI	0.93
GNLN	0.929
APLT	0.929
MORF	0.924
SBET	0.922
UFO	0.922

10 Most Negative Correlations
NTGR	-0.928
PI	-0.928
ATRS	-0.919
PPBT	-0.916
HONE	-0.912
CPSI	-0.912
BRAC	-0.908
KDNY	-0.907
MSAC	-0.903
LGTO	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acorda Therapeutics Inc Correlation - Currency/Commodity

0.78
( moderate )

0.00
( neutral )

0.67
( moderate )

0.00
( neutral )

-0.11
( neutral )

Acorda Therapeutics Inc Financials

Annual	2023
Revenue:	$117.63M
Gross Profit:	$71.59M (60.86 %)
EPS:	$-203.59

Q4	2023
Revenue:	$37.99M
Gross Profit:	$24.70M (65.02 %)
EPS:	$-225.81

Q3	2023
Revenue:	$27.72M
Gross Profit:	$24.33M (87.78 %)
EPS:	$-7.16

Q2	2023
Revenue:	$29.68M
Gross Profit:	$26.61M (89.67 %)
EPS:	$-7.55

Financial Reports:

No articles found.

Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.